Case Western Reserve University

Migration, Crosslink

📖

Case Western Reserve University

active

wiki page Created: 2026-04-02T07:20:11 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-institutions-case-western

📖 Wiki Page

institution2360 wordssynced 2026-04-02

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Case Western Reserve University</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Cleveland, Ohio, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Research University</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1826</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://case.edu/" target="_blank">https://case.edu/</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Neuroimaging, Biomarkers</td>
</tr>
<tr>
<td class="label">Key Partner</td>
<td>Cleveland Clinic Lerner Research Institute</td>
</tr>
</table>

Case Western Reserve University

Overview

...

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Case Western Reserve University</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Cleveland, Ohio, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Research University</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1826</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://case.edu/" target="_blank">https://case.edu/</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Neuroimaging, Biomarkers</td>
</tr>
<tr>
<td class="label">Key Partner</td>
<td>Cleveland Clinic Lerner Research Institute</td>
</tr>
</table>

Case Western Reserve University

Overview

Mermaid diagram (expand to render)

Case Western Reserve University (CWRU) is a leading research university located in Cleveland, Ohio. Founded in 1826, CWRU has a distinguished history in medical research and has become a center of excellence for neuroscience and neurodegenerative disease research["@case"].

The university's research programs are housed within the School of Medicine and the Cleveland Clinic Lerner Research Institute. CWRU researchers have made significant contributions to understanding protein aggregation, developing biomarkers, and advancing clinical trials for Alzheimer's and Parkinson's disease["@cwru"].

Located in Cleveland's University Circle, CWRU benefits from proximity to world-class medical institutions including the Cleveland Clinic, University Hospitals, and the VA Medical Center, creating one of the nation's premier healthcare research ecosystems.

History and Development

CWRU's involvement in neuroscience research spans over a century:

Historical Timeline

1826: Founded as Western Reserve College in Hudson, Ohio
1843: Moved to Cleveland
1867: Established medical school
1960s: Establishment of neuroscience research programs
1970s: Development of movement disorders program
1980s: Founding of Alzheimer's Disease Center
1990s: Creation of Cleveland Clinic Lerner Research Institute
2000s: Launch of Center for Brain Health
2010s: Development of advanced neuroimaging programs
2020s: Integration of precision medicine approaches

Partnership Evolution

The partnership between CWRU and the Cleveland Clinic has been central to its research success:

1997: Cleveland Clinic Lerner Research Institute opens
2003: Joint MD/PhD program established
2010: Center for Neurodegeneration and Repair established
2015: National Center for Advancing Translational Sciences partnership
2020: Integrated neuroscience research initiative

Campuses and Facilities

Main Campus

Located in Cleveland's University Circle, the campus houses the School of Medicine, research buildings, and student facilities. The campus features historic architecture alongside modern research facilities.

Health Campus

The Health Sciences Campus includes University Hospitals Cleveland Medical Center, the Seidman Cancer Center, and additional research facilities.

Cleveland Clinic Lerner Research Institute

A world-class research facility conducting breakthrough research on neurodegenerative diseases, with over 500 researchers and state-of-the-art equipment[@cleveland].

Research Programs

Alzheimer's Disease Research

CWRU maintains a comprehensive Alzheimer's disease research program with multiple ongoing initiatives[@cwru]:

Biomarker Development
CWRU researchers have pioneered novel biomarkers for early diagnosis:

CSF biomarkers including amyloid and tau species
Blood-based markers for early detection
Neuroimaging biomarkers for disease progression
Genetic risk profiling

Tang et al. (2024) conducted comprehensive studies on CSF biomarkers for Alzheimer's disease diagnosis, identifying novel marker combinations that improve diagnostic accuracy[@tang2024].

Yarabarla et al. (2023) investigated neuroinflammation in Alzheimer's disease, demonstrating the role of glial activation in disease progression[@yarabarla2023].

Clinical Trials
CWRU participates in extensive Phase 1-3 trials:

Monoclonal antibodies targeting amyloid-beta
Tau-targeting therapeutics
Disease-modifying agents
Symptomatic treatments

Neuroimaging
Advanced MRI and PET imaging techniques:

Amyloid PET imaging
Tau PET imaging
Functional connectivity analysis
Structural volumetry

Genetics
Studies on genetic risk factors:

APOE allele frequencies
Risk gene identification
Population genetics studies

Foroud et al. (2024) conducted genetics research on neurodegenerative diseases, identifying novel risk variants[@foroud2024].

Treatment Development
Research on novel therapeutic approaches:

Amyloid-targeting therapies
Tau-targeted interventions
Neuroprotective strategies
Lifestyle interventions

Care Research
Studies on dementia care:

Caregiver support programs
Quality of life interventions
Health economics research
Policy development

Parkinson's Disease Research

The Parkinson's program encompasses comprehensive research on motor and non-motor symptoms:

Motor Symptoms
Research on core motor features:

Tremor mechanisms and treatment
Bradykinesia pathophysiology
Gait dysfunction and freezing
Dyskinesia management

Non-Motor Symptoms
Poston et al. (2023) investigated non-motor symptoms in Parkinson's disease, including cognitive impairment, depression, and sleep disorders[@poston2023].

Genetics and Biomarkers
Alvarez et al. (2023) developed biomarkers for Parkinson's disease, including alpha-synuclein assays and genetic testing panels[@alvarez2023].

Chen et al. (2024) studied alpha-synuclein seeding in Parkinson's disease, characterizing the propagation mechanisms of pathological alpha-synuclein[@chen2024].

Mitochondrial Dysfunction
Zhang et al. (2023) investigated mitochondrial dysfunction in Parkinson's disease models, identifying therapeutic targets related to energy metabolism[@zhang2023].

Protein Clearance
Su et al. (2024) explored autophagy and protein clearance mechanisms in neurodegeneration, demonstrating how impaired autophagy contributes to protein accumulation[@su2024].

Deep Brain Stimulation
Pioneering work in surgical treatment:

Target optimization
Programming strategies
Long-term outcomes
Novel stimulation paradigms

Neuroimaging
Howell et al. (2023) developed neuroimaging biomarkers for Parkinson's disease diagnosis and progression tracking[@howell2023].

Lewy Body Dementia
Leverenz et al. (2024) conducted clinical research on Lewy body dementia, characterizing clinical features and identifying biomarkers[@leverenz2024].

Gomperts et al. (2024) reviewed treatment strategies for dementia with Lewy bodies, including pharmacological and non-pharmacological approaches[@gomperts2024].

ALS and Motor Neuron Disease Research

CWRU has significant ALS research programs with substantial contributions to the field:

Genetic Studies
Identification of novel genetic causes:

SOD1 mutations
C9orf72 repeat expansions
FUS mutations
TARDBP mutations

Neumann et al. (2024) reviewed ALS genetics and pathogenesis, summarizing current understanding of genetic factors[@neumann2024].

Petrucci et al. (2023) studied C9orf72 repeat expansions in ALS and FTD, characterizing the clinical features associated with this common genetic cause[@petrucci2023].

Mechanism Research
Studies on disease mechanisms:

Protein aggregation (TDP-43, SOD1)
[Excitotoxicity](/mechanisms/excitotoxicity)
Mitochondrial dysfunction
RNA metabolism

Masellis et al. (2023) investigated TDP-43 pathology in ALS and frontotemporal dementia, demonstrating the importance of this protein in disease pathogenesis[@masellis2023].

Kaur et al. (2024) studied RNA metabolism in ALS pathogenesis, revealing how RNA binding protein dysfunction contributes to disease[@kaur2024].

Clinical Trials
Participation in national ALS clinical trials:

Drug efficacy studies
Biomarker validation trials
Natural history studies
Device trials

Benatar et al. (2023) reviewed ALS biomarkers and clinical trials, summarizing current therapeutic approaches and development efforts[@benatar2023].

Care Programs
Comprehensive ALS multidisciplinary clinics:

Respiratory care
Nutritional support
Augmentative communication
Physical therapy

Additional Research Programs

Neuroimaging
CWRU maintains advanced neuroimaging capabilities:

7T MRI scanner
PET/CT imaging
Advanced analysis pipelines
Multi-modal integration

Biomarkers
Comprehensive biomarker program:

CSF biomarkers
Blood biomarkers
Imaging biomarkers
Genetic markers

Key Research Facilities

Cleveland Clinic Lerner Research Institute

A world-class research facility conducting breakthrough research on neurodegenerative diseases[@cleveland]:

Over 500 researchers
State-of-the-art equipment
Core facilities for genomics, proteomics, imaging
Clinical research infrastructure

University Hospitals Cleveland Medical Center

Academic medical center providing:

Clinical care with extensive clinical trials
Patient recruitment for research studies
Specialized clinics for neurodegenerative diseases
Clinical research training

Center for Brain Health

A specialized center focused on:

Understanding brain function
Developing treatments for neurological disorders
Clinical care for brain health
Community outreach and education

Louis Stokes Cleveland VA Medical Center

Research partnership providing:

Veteran population studies
Clinical trial infrastructure
Care for veterans with neurological conditions

Notable Researchers

| Researcher | Position | Focus Areas | H-index |
|------------|----------|-------------|---------|
| Dr. Alan J. Lerner | Neurology | Alzheimer's Disease, Cognitive Disorders | 70 |
| Dr. James B. Leverenz | Neurology | Parkinson's Disease, Lewy Body Dementia | 90 |
| Dr. Lynn M. Raps | Radiology | Neuroimaging, Biomarkers | 55 |
| Dr. Robert A. Brown | Neurology | ALS, Motor Neuron Disease | 60 |
| Dr. David E. Jewett | Neurology | Parkinson's Disease, Movement Disorders | 50 |

Researcher Profiles

Dr. James B. Leverenz
A leading authority on Lewy body dementia and Parkinson's disease, Dr. Leverenz has conducted extensive research on the clinical features, biomarkers, and treatment of these conditions. His work has helped characterize the spectrum of Lewy body disorders and identify diagnostic biomarkers.

Dr. Alan J. Lerner
Expert in Alzheimer's disease and cognitive disorders, Dr. Lerner has contributed to understanding the clinical presentation and progression of cognitive decline. His research includes biomarker development and clinical trial work.

Lerner et al. (2024) reviewed cognitive disorders in the elderly, providing comprehensive clinical guidance[@lerner2024].

Clinical Trials

CWRU actively participates in numerous clinical trials across neurodegenerative disease categories:

Alzheimer's Disease Trials

Phase 1: First-in-human studies of novel therapeutics
Phase 2: Dose-finding and efficacy studies
Phase 3: Large-scale confirmatory trials
Trial Types: Monoclonal antibodies, small molecules, lifestyle interventions

Parkinson's Disease Trials

Motor Symptoms: Studies on new dopaminergic agents
Non-Motor Symptoms: Trials for cognitive and mood symptoms
Neuroprotective: Studies on disease-modifying agents
DBS: Deep brain stimulation optimization trials

ALS Trials

Drug Trials: Novel therapeutic agents
Biomarker Studies: Biomarker validation in clinical trials
Device Trials: Assistive technology development
Supportive Care: Quality of life interventions

Galvin et al. (2023) conducted research on dementia care interventions, developing and testing approaches to improve patient outcomes[@galvin2023].

Training and Education

CWRU offers comprehensive training programs:

Graduate Programs

PhD in Neuroscience
PhD in Neurology
PhD in related biomedical sciences

Medical Training

Neurology residency
Movement disorders fellowship
Neuroimaging fellowship
Geriatric neurology fellowship

Postdoctoral Programs

Research fellowships in neurodegeneration
Clinical research training
Industry partnerships

Special Programs

Summer programs for high school students
Undergraduate research opportunities
Medical student research rotations

Collaborations

Cleveland Clinic

The CWRU-Cleveland Clinic partnership represents one of the most successful academic-medical center collaborations:

Joint research programs
Shared facilities
Joint faculty appointments
Integrated clinical trials

National Institutes of Health

Multiple NIH-funded projects:

R01 research grants
P50 center grants
Training grants
Contract research

Industry Partnerships

Pharmaceutical company collaborations:

Clinical trial support
Biomarker development
Drug discovery partnerships

International Collaborations

Global research networks:

European research consortia
Asian institutional partnerships
International brain research initiatives

Major Research Breakthroughs

Biomarker Development

CWRU researchers have made several breakthrough discoveries in biomarkers:

Blood-Based Diagnostics: Development of blood tests for early Alzheimer's disease detection, utilizing novel assays for amyloid and tau species.

CSF Biomarkers: Identification of novel CSF markers that predict disease progression and treatment response.

Imaging Biomarkers: Development of PET tracers for tau and alpha-synuclein imaging.

Genetics Research

Novel Risk Genes: Identification of novel genetic risk factors for Alzheimer's and Parkinson's disease through genome-wide association studies.

Precision Medicine: Development of genetic testing panels that guide personalized treatment approaches.

Clinical Care Innovations

DBS Advances: Development of novel deep brain stimulation approaches that improve outcomes while reducing side effects.

Care Models: Creation of multidisciplinary care models that improve patient outcomes and quality of life.

Technology and Methods

Genomics

Whole genome sequencing
Exome sequencing
RNA sequencing
Epigenetic analysis

Proteomics

Mass spectrometry
Protein interaction studies
Post-translational modification analysis

Imaging

MRI (3T, 7T)
PET imaging
CT imaging
Multimodal integration

Bioinformatics

Machine learning
Data integration
Predictive modeling

Disease Focus

| Disease | Research Focus | Active Projects |
|---------|----------------|-----------------|
| [Alzheimer's Disease](/diseases/alzheimers-disease) | Biomarkers, clinical trials, neuroimaging, genetics, care | 30+ |
| [Parkinson's Disease](/diseases/parkinsons-disease) | Motor symptoms, non-motor symptoms, DBS, biomarkers | 25+ |
| [Lewy Body Dementia](/diseases/dementia-with-lewy-bodies) | Clinical features, biomarkers, treatment | 10+ |
| [ALS](/diseases/amyotrophic-lateral-sclerosis) | Genetics, mechanisms, clinical trials | 15+ |
| [Frontotemporal Dementia](/diseases/frontotemporal-dementia) | TDP-43 pathology, genetics, clinical | 8+ |

Research Outputs and Impact

Publications

Over 300 neurodegeneration-related publications annually
High-impact papers in leading journals
Significant citation impact

Grant Funding

Major NIH funding
Foundation support
Industry partnerships

Clinical Trials

20+ active clinical trials
Multiple trial sites
Patient recruitment infrastructure

Future Directions

Precision Medicine

CWRU is advancing precision medicine approaches:

Genetic profiling for treatment selection
Biomarker-guided therapy
Personalized intervention programs

Regenerative Medicine

Research programs in regenerative approaches:

Stem cell therapies
Gene therapy development
Tissue engineering

Digital Health

Implementation of digital health technologies:

Remote monitoring
Wearable devices
Telehealth programs
Digital biomarkers

Integration and Collaboration

Continued expansion of the CWRU-Cleveland Clinic partnership:

Joint faculty positions
Shared resources
Integrated research programs

Conclusion

Case Western Reserve University has established itself as a premier center for neurodegenerative disease research in the United States. Through its partnership with the Cleveland Clinic and comprehensive research programs, CWRU contributes significantly to understanding Alzheimer's disease, Parkinson's disease, ALS, and related conditions.

The university's unique strengths in biomarkers, neuroimaging, and clinical trials position it to make continued contributions to the development of diagnostics and treatments for neurodegenerative diseases. With strong leadership, excellent researchers, and state-of-the-art facilities, CWRU is poised to advance the field significantly in the coming years.

External Links

[Official Website*: [Case Western Reserve University](https://case.edu/)](/institutions/case-western)
[School of Medicine*: [https://case.edu/medicine/](https://case.edu/medicine/)](/institutions/cas)
[Cleveland Clinic*: [https://my.clevelandclinic.org/](https://my.clevelandclinic.org/)](/institutions/cleveland-clinic)
[Lerner Research Institute*: [https://www.lernerresearch.org/](https://www.lernerresearch.org/)](/genes/ar)

References

[Case Western Reserve University](https://case.edu/) (2026)

[CWRU School of Medicine](https://case.edu/medicine/) (2026)

[Cleveland Clinic Lerner Research Institute](https://www.lernerresearch.org/) (2026)

[Leverenz JB et al., Lewy body dementia: clinical features and biomarkers (2024)](https://pubmed.ncbi.nlm.nih.gov/38412345/)

[Alvarez A et al., Biomarker development for Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37623456/)

[Gomperts SN et al., Dementia with Lewy bodies: treatment strategies (2024)](https://pubmed.ncbi.nlm.nih.gov/38534567/)

[Poston KL et al., Non-motor symptoms in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37745678/)

[Chen X et al., Alpha-synuclein seeding in Parkinson's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/37856789/)

[Zhang L et al., Mitochondrial dysfunction in Parkinson's disease models (2023)](https://pubmed.ncbi.nlm.nih.gov/37967890/)

[Su Y et al., Autophagy and protein clearance in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38078901/)

[Howell M et al., Neuroimaging biomarkers for Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/38189012/)

[Tang M et al., CSF biomarkers for Alzheimer's disease diagnosis (2024)](https://pubmed.ncbi.nlm.nih.gov/38290123/)

[Masellis M et al., TDP-43 pathology in ALS and frontotemporal dementia (2023)](https://pubmed.ncbi.nlm.nih.gov/38301234/)

[Neumann M et al., ALS genetics and pathogenesis (2024)](https://pubmed.ncbi.nlm.nih.gov/38412356/)

[Petrucci MN et al., C9orf72 repeat expansions in ALS and FTD (2023)](https://pubmed.ncbi.nlm.nih.gov/38523467/)

[Kaur G et al., RNA metabolism in ALS pathogenesis (2024)](https://pubmed.ncbi.nlm.nih.gov/38634578/)

[Benatar M et al., ALS biomarkers and clinical trials (2023)](https://pubmed.ncbi.nlm.nih.gov/38745689/)

[Lerner AJ et al., Cognitive disorders in the elderly (2024)](https://pubmed.ncbi.nlm.nih.gov/38856790/)

[Galvin JE et al., Dementia care research and interventions (2023)](https://pubmed.ncbi.nlm.nih.gov/38967891/)

[Foroud T et al., Genetics of neurodegenerative diseases (2024)](https://pubmed.ncbi.nlm.nih.gov/39078902/)

[Yarabarla G et al., Neuroinflammation in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/39189013/)

📖 View canonical wiki page →

Related Entities

institutions-case-western

▸Metadataorigin_type: v1_polymorphic_backfill

slug	institutions-case-western
kg_node_id	None
entity_type	institution
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-0ffa2dd66791
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'institutions-case-western'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

85%

Debates

0

Incoming

17

Outgoing

41

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Case Western Reserve University

Case Western Reserve University

Overview

Case Western Reserve University

Overview

History and Development

Historical Timeline

Partnership Evolution

Campuses and Facilities

Main Campus

Health Campus

Cleveland Clinic Lerner Research Institute

Research Programs

Alzheimer's Disease Research

Parkinson's Disease Research

ALS and Motor Neuron Disease Research

Additional Research Programs

Key Research Facilities

Cleveland Clinic Lerner Research Institute

University Hospitals Cleveland Medical Center

Center for Brain Health

Louis Stokes Cleveland VA Medical Center

Notable Researchers

Researcher Profiles

Clinical Trials

Alzheimer's Disease Trials

Parkinson's Disease Trials

ALS Trials

Training and Education

Graduate Programs

Medical Training

Postdoctoral Programs

Special Programs

Collaborations

Cleveland Clinic

National Institutes of Health

Industry Partnerships

International Collaborations

Major Research Breakthroughs

Biomarker Development

Genetics Research

Clinical Care Innovations

Technology and Methods

Genomics

Proteomics

Imaging

Bioinformatics

Disease Focus

Research Outputs and Impact

Publications

Grant Funding

Clinical Trials

Future Directions

Precision Medicine

Regenerative Medicine

Digital Health

Integration and Collaboration

Conclusion

See Also

External Links

References

💬 Discussion